Yadav Hariom, Jain Shalini, Prasad G B K S, Yadav Mukesh
School of Studies in Biochemistry, Jiwaji University, Gwalior-474011, Madhya Prakesh, India.
J Pharmacol Sci. 2007 Sep;105(1):12-21. doi: 10.1254/jphs.fp0060092. Epub 2007 Sep 12.
In the present study, the polyherbal preparation diabegon, containing 18 plant extracts with hypoglycemic activity, was evaluated for its preventive effect during progression of type 2 diabetes in high-fructose-diet-fed rats. Oral administration of diabegon (100 mg/kg body weight) delayed development of glucose intolerance for 4 weeks in comparison with the diabetic control group, and the effect of diabegon was compared to that of the standard insulin sensitizer drug rosiglitazone. Diabegon treatment also ameliorated the elevation of glycosylated haemoglobin, liver glycogen content, plasma insulin, homeostasis model assessment, free fatty acids, triglycerides, total cholesterol, LDL-cholesterol, and VLDL-cholesterol, whereas it increased HDL-cholesterol after 56 days of treatment (P<0.05). The mechanism of action by which diabegon attenuates insulin resistance and dyslipidemia may be through induction of peroxisome proliferator-activated receptor-gamma and lipoprotein lipase activity in peripheral tissues (muscles). Moreover, diabegon administration for 56 days also produced no alteration in liver and kidney function tests, which seems to indicate its non-toxicity during treatment. Our present results suggest that diabegon may be included in diabetes mellitus treatment regimens, as a drug with good antidiabetic actions but no toxic manifestations.
在本研究中,对含有18种具有降血糖活性植物提取物的多草药制剂diabegon,在高果糖饮食喂养的大鼠2型糖尿病进展过程中的预防作用进行了评估。与糖尿病对照组相比,口服diabegon(100毫克/千克体重)可使葡萄糖耐量异常的发展延迟4周,并将diabegon的效果与标准胰岛素增敏剂药物罗格列酮的效果进行了比较。diabegon治疗还改善了糖化血红蛋白、肝糖原含量、血浆胰岛素、稳态模型评估、游离脂肪酸、甘油三酯、总胆固醇、低密度脂蛋白胆固醇和极低密度脂蛋白胆固醇的升高,而在治疗56天后它增加了高密度脂蛋白胆固醇(P<0.05)。diabegon减轻胰岛素抵抗和血脂异常的作用机制可能是通过诱导外周组织(肌肉)中的过氧化物酶体增殖物激活受体γ和脂蛋白脂肪酶活性。此外,给予diabegon 56天对肝肾功能检查也没有产生改变,这似乎表明其在治疗期间无毒。我们目前的结果表明,diabegon可作为一种具有良好抗糖尿病作用且无毒性表现的药物纳入糖尿病治疗方案。